Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication
| Status: | Completed |
|---|---|
| Conditions: | Hospital |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/6/2019 |
| Start Date: | September 2008 |
| End Date: | December 2011 |
Programming Implantable Cardioverter Defibrillators (ICDs) in Patients With Primary Prevention Indication to Prolong Time to First Shock
Although shock therapy is effective in terminating ventricular tachycardia (VT), it can be
painful to the patient and repetitive shocks can decrease a patient's quality of life.
Previous studies have suggested that one or more sets of aggressive device parameter settings
may reduce the total number of shocks in primary prevention patients. In addition to shock
therapies, antitachycardia pacing (ATP) is also available in ICDs to treat VT. The PROVIDE
trial aims to prospectively study the effect of high detection rates, prolonged detection
intervals, aggressive SVT discriminators, and extensive ATP therapy in prolonging the time to
first shock in primary prevention patients.
painful to the patient and repetitive shocks can decrease a patient's quality of life.
Previous studies have suggested that one or more sets of aggressive device parameter settings
may reduce the total number of shocks in primary prevention patients. In addition to shock
therapies, antitachycardia pacing (ATP) is also available in ICDs to treat VT. The PROVIDE
trial aims to prospectively study the effect of high detection rates, prolonged detection
intervals, aggressive SVT discriminators, and extensive ATP therapy in prolonging the time to
first shock in primary prevention patients.
Inclusion Criteria:
- Primary Prevention indication for ICD/ CRT-D
Exclusion Criteria:
- No prior documented history of spontaneous VT/VF
We found this trial at
1
site
Click here to add this to my saved trials
